Cargando…

Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study

Pertussis is a highly contagious disease, for which periodic peaks in incidence and an increasing number of outbreaks have been observed over the last decades. The reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine (Tdap) can be used to boost individuals aged ≥10 years, vaccinate...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovac, Martina, Kostanyan, Lusiné, Mesaros, Narcisa, Kuriyakose, Sherine, Varman, Meera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149833/
https://www.ncbi.nlm.nih.gov/pubmed/29630439
http://dx.doi.org/10.1080/21645515.2018.1460292
_version_ 1783356878682587136
author Kovac, Martina
Kostanyan, Lusiné
Mesaros, Narcisa
Kuriyakose, Sherine
Varman, Meera
author_facet Kovac, Martina
Kostanyan, Lusiné
Mesaros, Narcisa
Kuriyakose, Sherine
Varman, Meera
author_sort Kovac, Martina
collection PubMed
description Pertussis is a highly contagious disease, for which periodic peaks in incidence and an increasing number of outbreaks have been observed over the last decades. The reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine (Tdap) can be used to boost individuals aged ≥10 years, vaccinated in infancy with a diphtheria-tetanus-acellular pertussis vaccine (DTaP), to reduce pertussis morbidity and maintain protection against diphtheria and tetanus throughout adolescence and adulthood. This phase III, open-label, non-randomized, multicenter follow-up study (NCT01738477) enrolled 19–30-year-old participants from the United States who had received booster vaccination 10 years earlier with either Tdap (Tdap group) or Td (Td group). In total, 128 (Tdap group) and 37 (Td group) participants received Tdap vaccination. After administration of Tdap, all participants were seroprotected (antibody concentrations ≥0.1 international units [IU]/ml) against diphtheria and tetanus. Immune responses to a second Tdap dose in the Tdap group were shown to be non-inferior to responses elicited by a first Tdap dose in the Td group for diphtheria and tetanus and to a 3-dose DTaP vaccination during infancy for pertussis antigens (primary objectives). Post-booster vaccination, all participants in both groups had antibody concentrations above assay cut-offs and antibody geometric mean concentrations increased by 3.8–15.5-fold compared to pre-booster levels for all antigens. The incidence of adverse events was similar in the Td (80.6%) and Tdap (85.6%) groups (no serious adverse events reported). A Tdap dose administered after previous Td or Tdap vaccination was shown to be immunogenic and well-tolerated in young adults, supporting repeated vaccination with Tdap at 10-year intervals.
format Online
Article
Text
id pubmed-6149833
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-61498332018-09-24 Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study Kovac, Martina Kostanyan, Lusiné Mesaros, Narcisa Kuriyakose, Sherine Varman, Meera Hum Vaccin Immunother Research Paper Pertussis is a highly contagious disease, for which periodic peaks in incidence and an increasing number of outbreaks have been observed over the last decades. The reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine (Tdap) can be used to boost individuals aged ≥10 years, vaccinated in infancy with a diphtheria-tetanus-acellular pertussis vaccine (DTaP), to reduce pertussis morbidity and maintain protection against diphtheria and tetanus throughout adolescence and adulthood. This phase III, open-label, non-randomized, multicenter follow-up study (NCT01738477) enrolled 19–30-year-old participants from the United States who had received booster vaccination 10 years earlier with either Tdap (Tdap group) or Td (Td group). In total, 128 (Tdap group) and 37 (Td group) participants received Tdap vaccination. After administration of Tdap, all participants were seroprotected (antibody concentrations ≥0.1 international units [IU]/ml) against diphtheria and tetanus. Immune responses to a second Tdap dose in the Tdap group were shown to be non-inferior to responses elicited by a first Tdap dose in the Td group for diphtheria and tetanus and to a 3-dose DTaP vaccination during infancy for pertussis antigens (primary objectives). Post-booster vaccination, all participants in both groups had antibody concentrations above assay cut-offs and antibody geometric mean concentrations increased by 3.8–15.5-fold compared to pre-booster levels for all antigens. The incidence of adverse events was similar in the Td (80.6%) and Tdap (85.6%) groups (no serious adverse events reported). A Tdap dose administered after previous Td or Tdap vaccination was shown to be immunogenic and well-tolerated in young adults, supporting repeated vaccination with Tdap at 10-year intervals. Taylor & Francis 2018-05-10 /pmc/articles/PMC6149833/ /pubmed/29630439 http://dx.doi.org/10.1080/21645515.2018.1460292 Text en © 2018 The Author(s). Published with license by Taylor & Francis http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Paper
Kovac, Martina
Kostanyan, Lusiné
Mesaros, Narcisa
Kuriyakose, Sherine
Varman, Meera
Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study
title Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study
title_full Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study
title_fullStr Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study
title_full_unstemmed Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study
title_short Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study
title_sort immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: an open, phase iii, non-randomized, multi-center study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149833/
https://www.ncbi.nlm.nih.gov/pubmed/29630439
http://dx.doi.org/10.1080/21645515.2018.1460292
work_keys_str_mv AT kovacmartina immunogenicityandsafetyofasecondboosterdoseofanacellularpertussisvaccinecombinedwithreducedantigencontentdiphtheriatetanustoxoids10yearsafterafirstboosterinadolescenceanopenphaseiiinonrandomizedmulticenterstudy
AT kostanyanlusine immunogenicityandsafetyofasecondboosterdoseofanacellularpertussisvaccinecombinedwithreducedantigencontentdiphtheriatetanustoxoids10yearsafterafirstboosterinadolescenceanopenphaseiiinonrandomizedmulticenterstudy
AT mesarosnarcisa immunogenicityandsafetyofasecondboosterdoseofanacellularpertussisvaccinecombinedwithreducedantigencontentdiphtheriatetanustoxoids10yearsafterafirstboosterinadolescenceanopenphaseiiinonrandomizedmulticenterstudy
AT kuriyakosesherine immunogenicityandsafetyofasecondboosterdoseofanacellularpertussisvaccinecombinedwithreducedantigencontentdiphtheriatetanustoxoids10yearsafterafirstboosterinadolescenceanopenphaseiiinonrandomizedmulticenterstudy
AT varmanmeera immunogenicityandsafetyofasecondboosterdoseofanacellularpertussisvaccinecombinedwithreducedantigencontentdiphtheriatetanustoxoids10yearsafterafirstboosterinadolescenceanopenphaseiiinonrandomizedmulticenterstudy